OakChart

Parabilis Medicines Inc

PBLSHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 8:18 AM ET

30.00-0.02 (-0.07%)
2026-11-11 14:57 CET
Market cap
3,708.46 USD m
Revenue, TTM
0.15 USD m
Net income, TTM
-66.95 USD m
Free cash flow, TTM
-4.24 USD m
EPS diluted, TTM
-0.54
P/E
-
Compare

Price

PBLS against its 20 and 50-day averages
2050earnings
25.0030.0035.0040.004.5M9.1MJun 26Jul 26Aug 26Sep 26Oct 26Nov 26PBLSclose 30.0020-day 27.5050-day 31.3730.00

29.4% under 42.49 on 18 Sep 2026. Last 15 sessions, 36.6% high to low

Profile

PBLS
52-week range, 37% of the way up
22.6642.49

Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

IndexRUT
IPOJun 10, 2026
ATR, 14d2.22
Rel volume0.05
Short float14.26%
Insider own37.28%
Inst own51.85%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.71B
Enterprise Value2.63B
Income-
Sales-
Book/sh8.48
Cash/sh9.07
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOJun 10, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.54
P/C3.31
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio17.91
Current Ratio17.91
Debt/Eq0.05
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-0.36
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
EarningsAug 13 BMO
EPS/Sales Surpr.-1306.06% -99.30%

Ownership

Insider Own37.28%
Insider Trans91.17%
Inst Own51.85%
Inst Trans113.62%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA209.10%
SMA50-4.36%
SMA200-6.23%
Trades-

Technical

Shs Outstand121.94M
Shs Float77.48M
Short Float14.26%
Short Ratio11.98
Short Interest11.05M
52W High42.49 -29.39%
52W Low22.66 32.39%
Volatility7.77% 8.95%
ATR (14)2.22
RSI (14)53.18
Beta-
Rel Volume0.05
Avg Volume922.61K
Volume2,368

Performance

Perf Week-1.19%
Perf Month11.73%
Perf Quarter-15.90%
Perf Half Y-
Perf YTD-10.04%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price41.00
Prev Close30.02
Price30.00
Change %-0.07%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Nov 09, 2026InitiatedCCanaccord GenuityBuy$39+30.0%
Oct 22, 2026InitiatedHH.C. WainwrightBuy$40+33.3%
Jul 06, 2026InitiatedLLeerink PartnersOutperform$40+33.3%
Jul 06, 2026InitiatedGGuggenheimBuy$40+33.3%
Jul 06, 2026InitiatedEEvercore ISIOutperform
Jul 06, 2026InitiatedBBofA SecuritiesBuy$45+50.0%

Peers

Mkt cap
TickerCompanyMkt cap
RLAYRelay Therapeutics Inc4.42B
IMNMImmunome Inc2.19B
IDYAIdeaya Biosciences Inc3.07B
TNGXTango Therapeutics Inc4.21B
ERASErasca Inc5.26B
RVMDRevolution Medicines Inc42.18B
KYMRKymera Therapeutics Inc11.67B
CELCCelcuity Inc3.38B
ELVNEnliven Therapeutics Inc3.77B
ARVNArvinas Inc449.23M

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RA CAPITAL MANAGEMENT, L.P.DirectorJul 20 '26Buy27.28131,4203,584,88726,416,513Jul 22 04:55 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 21 '26Buy29.2565,9231,928,03226,482,436Jul 22 04:55 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 22 '26Buy29.7747,2501,406,63226,529,686Jul 22 04:55 PM
Levy Guy10% OwnerJun 11 '26Buy20.00500,00010,000,0001,027,000Jun 29 10:41 AM
SEBULSKY ALANDirectorJun 15 '26Buy26.499,065240,13530,000Jun 16 06:19 PM
SEBULSKY ALANDirectorJun 12 '26Buy27.678,435233,39320,935Jun 16 06:19 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJun 11 '26Buy20.0021,188,750423,775,00026,285,093Jun 15 06:57 PM
SEBULSKY ALANDirectorJun 11 '26Buy20.0012,500250,00012,500Jun 15 05:27 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-2.320-0.165-0.4100.1216.674
2026Q12026-06-03-0.720--0.6000.00--
2026Q3---0.360--0.385
2026Q4---0.376--0.755
2027Q1---0.386--1.754
2027Q2---0.397--2.204
2027Q3---0.403--2.554
2027Q4---0.409--3.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-214000.380.001.00
2026Q3S2026-08-133000.330.001.00
2026Q3S2026-07-062000.000.000.00
2026Q3S2026-07-021000.000.000.00
2026Q3R2026-10-28100-0.45-0.45-0.45
2026Q3R2026-08-14101-0.45-0.45-0.45
2026Q3R2026-08-13100-0.43-0.43-0.43
2026Q3R2026-07-06100-0.43-0.43-0.43
2026Q3E2026-11-09500-0.36-0.45-0.25
2026Q3E2026-11-06600-0.39-0.56-0.25
2026Q3E2026-10-28500-0.36-0.45-0.25
2026Q3E2026-10-27501-0.36-0.45-0.25
2026Q3E2026-10-21512-0.36-0.45-0.25
2026Q3E2026-08-14412-0.36-0.45-0.25

Estimate history

EPS, annual-1.367-1.582
Period20242025
EPS, quarterly-0.407-0.364-0.6-0.542
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Sales, annual00
Period20242025
Sales, quarterly0000.148
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Shares, annual118.146118.146123.52
Period20242025MRQ
Shares, quarterly118.146123.52118.146123.52
PeriodQ1 '25Q2 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY
Total Revenue0.150.000.00
Cost of Goods Sold Incl. D&A0.592.502.11
Gross Profit-0.45-2.50-2.11
Selling, General and Administrative Excl. Other50.44149.58124.02
Research and Development39.38125.01100.74
Other Operating Expense0.000.000.00
Operating Income-50.89-152.08-126.12
Interest Expense0.211.521.49
Unusual Expense5.560.000.97
Net Income Before Taxes-52.46-145.89-117.91
Income Taxes0.000.000.00
Consolidated Net Income-52.46-145.89-117.91
Net Income From Continuing Operations-52.46-145.89-117.91
Net Income-66.95-186.93-161.48
EPS (Recurring)-0.51-1.58-1.36
EPS (Basic, Before Extraordinaries)-0.54-1.58-1.37
EPS (Diluted)-0.54-1.58-1.37
EBITDA-50.29-149.58-124.02
Non-Operating Income (Expense)4.197.7110.67
Other After Tax Adjustments0.000.000.00
Stock Option Compensation Expense3.633.324.31
Shares Outstanding123.52118.15118.15
Market Capitalization3,708.463,708.46-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Total Revenue0.150.000.000.00
Cost of Goods Sold Incl. D&A0.590.610.620.65
Gross Profit-0.45-0.61-0.62-0.65
Selling, General and Administrative Excl. Other50.4446.8535.9039.59
Research and Development39.3837.6530.1333.80
Other Operating Expense0.000.000.000.00
Operating Income-50.89-47.45-36.52-40.24
Interest Expense0.210.290.400.40
Unusual Expense5.560.000.000.00
Net Income Before Taxes-52.46-45.32-34.81-38.33
Income Taxes0.000.000.000.00
Consolidated Net Income-52.46-45.32-34.81-38.33
Net Income From Continuing Operations-52.46-45.32-34.81-38.33
Net Income-66.95-70.88-44.99-48.11
EPS (Recurring)-0.51-0.60-0.36-0.41
EPS (Basic, Before Extraordinaries)-0.54-0.60-0.36-0.41
EPS (Diluted)-0.54-0.60-0.36-0.41
EBITDA-50.29-46.85-35.90-39.59
Non-Operating Income (Expense)4.192.432.112.31
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense3.631.300.820.85
Gross Margin-300.68---
Operating Margin-34,382.43---
Net Margin-45,239.86---
Shares Outstanding123.52118.15123.52118.15
Market Capitalization3,708.463,448.68--

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY
Cash & Short Term Investments27.7187.98
Short Term Receivables0.000.36
Inventories0.000.00
Other Current Assets1.653.87
Total Current Assets29.3692.21
Net Property, Plant & Equipment46.0852.93
Total Investments and Advances2.852.85
Deferred Tax Assets11.1112.59
Other Assets2.531.26
Total Assets91.93161.85
Short Term Debt Incl. Current Port. of LT Debt20.899.38
Accounts Payable17.279.51
Other Current Liabilities18.6313.52
Total Current Liabilities56.7932.41
Long Term Debt37.8156.82
Provision for Risks Charges0.000.00
Deferred Tax Liabilities11.1112.59
Other Liabilities2.743.58
Total Liabilities108.45105.41
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value509.97440.38
Common Equity-526.50-383.94
Total Shareholders Equity-16.5256.44
Accumulated Minority Interest0.000.00
Total Equity-16.5256.44
Total Liabilities & Stockholders Equity91.93161.85
Book Value Per Share-4.46-3.25
Tangible Book Value Per Share-4.46-3.25
Price to Book Ratio3.54-
Return on Assets-114.98-
Return on Equity-731.00-
Return on Invested Capital-685.34-104.11
Quick Ratio0.522.84
Current Ratio0.522.84

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY
Net Income-52.46-145.89-117.91
Depreciation0.592.502.11
Other Funds (Non Cash)10.7310.5611.27
Funds from Operations-41.14-132.83-104.54
Extraordinary Item0.000.000.00
Changes in Working Capital37.529.120.91
Cash from Operating Activities-3.62-123.71-103.63
Capital Expenditures-0.62-0.31-0.88
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments-33.4540.0631.12
Purchase of Investments-33.45-16.66-90.86
Sale Or Maturity of Investments0.0056.73121.98
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities-34.0639.7630.24
Cash Dividends Paid0.000.000.00
Change in Capital Stock849.6167.4678.08
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock849.6167.4678.08
Proceedsfrom Stock Options849.0367.4377.01
Issuance or Reduction of Debt, Net-3.91-3.080.00
Change in Long Term Debt-3.91-3.080.00
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt-3.91-3.080.00
Net Financing Active Other Cash Flow-50.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities795.7164.3878.08
Net Change in Cash758.02-19.574.70
Free Cash Flow-4.24-124.02-104.51
Deferred Taxes & Investment Tax Credit-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Cash & Short Term Investments1,120.70329.04--
Short Term Receivables0.000.00--
Inventories0.000.00--
Other Current Assets4.703.03--
Total Current Assets1,125.40332.07--
Net Property, Plant & Equipment42.7344.35--
Total Investments and Advances2.852.85--
Other Assets4.294.89--
Total Assets1,175.26384.17--
Short Term Debt Incl. Current Port. of LT Debt13.9717.43--
Accounts Payable18.5215.04--
Other Current Liabilities30.3421.77--
Total Current Liabilities62.8454.24--
Long Term Debt33.5435.71--
Provision for Risks Charges0.000.00--
Other Liabilities31.1550.00--
Total Liabilities127.53139.95--
Non-Equity Reserves0.000.00--
Preferred Stock - Carrying Value0.00814.54--
Common Equity1,047.73-570.32--
Total Shareholders Equity1,047.73244.22--
Accumulated Minority Interest0.000.00--
Total Equity1,047.73244.22--
Total Liabilities & Stockholders Equity1,175.26384.17--
Book Value Per Share8.48-4.83--
Tangible Book Value Per Share8.48-4.83--
Full-Time Employees-176--
Price to Book Ratio3.54-6.05--
Return on Invested Capital-4.85-16.19--
Quick Ratio17.916.12--
Current Ratio17.916.12--

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Net Income-52.46-45.32-34.81-38.33
Depreciation0.590.610.620.65
Other Funds (Non Cash)10.733.042.732.65
Funds from Operations-41.14-41.67-31.46-35.02
Extraordinary Item0.000.000.000.00
Changes in Working Capital37.52-7.530.370.87
Cash from Operating Activities-3.62-49.20-31.09-34.15
Capital Expenditures-0.62-0.37-0.02-0.07
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments-33.450.0024.536.76
Purchase of Investments-33.450.000.00-16.66
Sale Or Maturity of Investments0.000.0024.5323.43
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities-34.06-0.3724.516.69
Cash Dividends Paid0.000.000.000.00
Change in Capital Stock849.61304.800.0167.43
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock849.61304.800.0167.43
Proceedsfrom Stock Options849.03304.610.0067.43
Issuance or Reduction of Debt, Net-3.91-3.90-0.14-0.14
Change in Long Term Debt-3.91-3.90-0.14-0.14
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt-3.91-3.90-0.14-0.14
Net Financing Active Other Cash Flow-50.0050.000.000.00
Other Financing Activities Uses0.000.000.000.00
Cash from Financing Activities795.71350.90-0.1467.29
Net Change in Cash758.02301.33-6.7139.82
Free Cash Flow-4.24-49.57-31.11-34.23

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.26%11.1M77.5M884.95K
2026-10-1511.94%9.3M77.5M724.25K
2026-09-3010.66%8.3M77.5M640.59K
2026-09-157.86%6.1M77.5M521.99K
2026-08-317.32%5.5M75.4M659.79K
2026-08-146.97%5.3M75.4M723.31K
2026-07-315.75%5.1M89.1M830.44K
2026-07-154.44%4.0M89.1M1.04M
2026-06-303.11%2.8M89.1M1.45M
2026-06-151.22%1.1M91.3M2.35M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.0013.1017.500.005.6870.000.000.893-0.2410.009
call17.5010.6015.000.004.7390.000.000.868-0.2320.011
call20.009.0012.5010.503.9286.000.000.839-0.2190.012
call22.506.1010.000.003.5570.000.000.784-0.2650.014
call25.003.808.000.002.8571.000.000.729-0.3380.016
call30.000.004.001.191.82444.000.000.599-0.2300.020
call35.000.004.900.352.6333.000.000.481-0.2700.021
call40.000.004.900.353.29038.000.000.427-0.3320.020
call45.000.004.902.303.8037.000.000.395-0.3770.020
call50.000.004.901.504.22812.000.000.374-0.4120.020
call55.000.004.900.004.5890.000.000.358-0.4400.019
call60.000.004.900.134.9042.000.000.346-0.4650.019
put15.000.004.900.305.2493.000.00-0.101-0.2380.009
put17.500.004.900.004.3900.000.00-0.124-0.2300.011
put20.000.002.000.603.55412.000.00-0.161-0.2170.012
put22.500.003.001.693.5881.000.00-0.216-0.2620.014
put25.000.004.900.704.2361500.00-0.253-0.3460.017
put30.000.104.903.002.52610.000.00-0.424-0.2220.019
put35.003.107.905.302.18515.000.00-0.531-0.2890.020
put40.008.0012.504.502.8060.000.00-0.577-0.3460.019
put45.0013.0017.500.003.2950.000.00-0.606-0.3890.019
put50.0018.0022.500.003.7020.000.00-0.626-0.4220.019
put55.0023.0027.500.004.0510.000.00-0.640-0.4500.018
put60.0028.0032.500.004.3560.000.00-0.652-0.4730.018

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-10-30SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-09-028-KCurrent report2026-08-28SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-22SEC
2026-08-253Initial statement of beneficial ownership of securities2026-08-22SEC
2026-08-258-KCurrent report2026-08-22SEC
2026-08-14SCHEDULE 13GSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-06SCHEDULE 13GSEC
2026-07-224Statement of changes in beneficial ownership of securities2026-07-20SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-293Initial statement of beneficial ownership of securities2026-06-09SEC
2026-06-18SCHEDULE 13DSEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-118-KCurrent report2026-06-09SEC
2026-06-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-076.92M300
2026-06434.50M500
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.24.49%
FMR LLC8.80%
ARCH Venture Management, LLC5.43%
venBio Partners LLC4.46%
Alphabet Inc.3.98%
Nextech Invest Ltd.3.95%
REGENERON PHARMACEUTICALS, INC.3.37%
Siren, L.L.C.2.53%
FARALLON CAPITAL MANAGEMENT, L.L.C.2.00%
Jupiter Topco LLC1.94%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.95%
Fidelity Growth Company Fund0.90%
VANGUARD SMALL-CAP INDEX FUND0.68%
Select Health Care Portfolio0.46%
Fidelity Advisor Biotechnology Fund0.45%
T. Rowe Price Health Sciences Fund, Inc.0.41%
JPMorgan Small Cap Growth Fund0.41%
Select Biotechnology Portfolio0.35%
AB Small Cap Growth Portfolio0.28%
Fidelity Small Cap Growth Fund0.27%

OakChart. PBLS. Cached 15 minutes.

Some panels did not load: news.